The primary objective of this study is to evaluate the safety and tolerability of JAB-BX102 monotherapy to determine the MTD(maximum tolerated dose) and RP2D(Recommended Phase 2 Dose) during Dose Escalation phase.

Inclusion Criteria:

Must be able to provide an archived tumor sample
Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor
Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition
Must have at least 1 measurable lesion per RECIST v1.1
Must have adequate organ functions

Locations
China, Anhui
The First Affiliated Hospital of Bengbu Medical College 
Bengbu, Anhui, China, 233004
China, Beijing
Cancer Hospital Chinese Academy of Medical Sciences 
Beijing, Beijing, China, 100021
Peking University Third Hospital 
Beijing, Beijing, China, 100191
China, Henan
The First Affiliated Hospital of Zhengzhou University 
Zhengzhou, Henan, China, 450052
China, Hunan
Hunan Cancer Hospital 
Changsha, Hunan, China, 410013
China, Shanghai
Huashan Hospital 
Shanghai, Shanghai, China, 200040

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05174585